Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-05-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894018769305 |